Profound Medical (NASDAQ:PROF; TSX:PRN) will unveil interim five-year follow-up data from its TACT (TULSA-PRO ablation clinical trial) pivotal study at a live webinar event it is hosting on June 6 at 6 pm ET.
The webinar will also feature a number of esteemed TUSLA-PRO users who will share their firsthand experiences with the technology.
They include Y. Mark Hong, M.D., from Integrative Urology, Phoenix;. Stephen Scionti, M.D., from Scionti Prostate Center / HALO Precision Diagnostics; Daniel Costa, M.D., from UT Southwestern; and Xiaosong Meng, M.D., Ph.D., from UT Southwestern.
In August 2019, Profound received the FDA clearance to commercialize its TULSA-PRO device based on results of the TACT clinical trial. The device also is CE marked in Europe and Health Canada approved to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities.
Those interested may register for the webinar here.
